Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.54 GBX | -0.22% | -4.42% | -37.38% |
Apr. 26 | Earnings Flash (ROQ.L) ROQUEFORT THERAPEUTICS Reports FY23 Loss GBX-1.35 | MT |
Apr. 26 | Roquefort Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Number of employees: 9
Sales per Business
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biotechnology
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Sales per region
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United Kingdom, Europe and Australia
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ajan Reginald
CEO | Chief Executive Officer | 52 | 22-09-15 |
Chairman | 51 | 20-08-16 | |
Armand Keating
CTO | Chief Tech/Sci/R&D Officer | - | 22-09-15 |
Martin Evans
CTO | Chief Tech/Sci/R&D Officer | 83 | 22-09-15 |
Graham Robertson
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jean Duvall
BRD | Director/Board Member | 63 | 22-04-04 |
Darrin Disley
BRD | Director/Board Member | 57 | 22-09-15 |
Chairman | 51 | 20-08-16 | |
Martin Evans
CTO | Chief Tech/Sci/R&D Officer | 83 | 22-09-15 |
Ajan Reginald
CEO | Chief Executive Officer | 52 | 22-09-15 |
Michael Stein
BRD | Director/Board Member | 60 | 21-03-21 |
Simon Sinclair
BRD | Director/Board Member | 52 | 22-04-19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 129,149,998 | 37,475,657 ( 29.02 %) | 0 | 29.02 % |
Company contact information
Roquefort Therapeutics Plc
Eccleston Yards 25 Eccleston Place
SW1W 9NF, London
+44 20 3918 8633
http://www.roquefortplc.comSector
1st Jan change | Capi. | |
---|---|---|
-37.38% | 7.32M | |
-5.55% | 113B | |
+20.42% | 63.85B | |
+5.53% | 61.9B | |
+10.97% | 42.86B | |
+9.74% | 40.84B | |
+18.55% | 34.58B | |
+5.68% | 25.46B | |
-4.69% | 22.13B | |
+2.12% | 18.61B |
- Stock Market
- Equities
- ROQ Stock
- Company Roquefort Therapeutics plc